Investigation of the Genetic and Environmental Determinants of MP Including Response to Supplementation

This study is currently recruiting participants.
Verified January 2013 by Queen's University, Belfast
Sponsor:
Information provided by (Responsible Party):
Ruth Hogg, Queen's University, Belfast
ClinicalTrials.gov Identifier:
NCT01778231
First received: January 25, 2013
Last updated: January 28, 2013
Last verified: January 2013

January 25, 2013
January 28, 2013
March 2011
May 2013   (final data collection date for primary outcome measure)
Macular Pigment Measurement [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
Macular Pigment Measurement using Heterochromatic Flicker Photometry
Same as current
Complete list of historical versions of study NCT01778231 on ClinicalTrials.gov Archive Site
  • Serum Lutein and Zeaxanthin [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
  • Macular Pigment (reflectometry) [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    Macular Pigment level measured using reflectometry
Same as current
Not Provided
Not Provided
 
Investigation of the Genetic and Environmental Determinants of MP Including Response to Supplementation
Investigation of the Genetic and Environmental Determinants of MP Including Response to Supplementation

This study aims to investigate genetic and environmental determinants of macular pigment (MP) and assess the effects of lutein and zeaxanthin-rich supplements on macular pigment levels.

Age-related macular degeneration is the leading cause of blindness in elderly people in western countries1. It is a degenerative condition of the macula characterized by the death or dysfunction of photoreceptors, leading to the progressive loss of central vision1. Central vision is needed for activities requiring fine vision such as reading, driving or recognizing faces. With the aging population and increasing expectations in health care it is therefore of utmost importance to preserve the quality of life and independence of the elderly through prevention of this ocular disease.

Much interest surrounds macular pigment due to its putative role in protecting the macula from oxidative stress and age-related degenerative change2, yet much is still unknown about factors that determine its uptake and deposition. Large inter-individual differences in MP have been demonstrated with several large population based studies showing that peak macular pigment density can vary by over a factor of 10 between individuals3-4. Subsequent studies have suggested a number of parameters such as age, diet, percentage body fat, gender and tobacco use5-9 as determinants of MP, however these only account for approximately a third of the variance leaving a significant proportion unexplained.

Lutein and Zeaxanthin (L and Z), constituents of MP, cannot be synthesized by the body and so are entirely dietary in origin. They are present in foods such as collard greens, spinach and Brussels sprouts10. Variation in the bitter-taste receptor gene, TAS2R38 confers the ability to taste 6-n-propylthiouracil (PROP) and phenylthiocarbamide (PTC) which is present in many of these foods11. People who taste PTC with a greater intensity are more likely to avoid these foods and therefore we hypothesize they may have lower levels of macular pigment. Thus, this study may help to identify a group at higher risk of macular degeneration.

Despite MP's dietary origin only modest correlations exist with serum and dietary levels of L and Z, and although the level of MP can be augmented in most people by diet or supplementation the response is variable and not always correlated with baseline level. Most supplementation studies identify a sub-group of "retinal non-responders"12 in which serum values of the carotenoids have risen, yet no change is found in macular pigment, the reason for this is not clear. The first part of our study will provide a well-phenotyped group in which to explore this further. Several studies have also shown that peak macular pigment levels are strongly heritable13-14 suggesting genetics may play an important role. Although no gene has currently been clearly identified the ApoE gene has been suggested to show an association with macular pigment level. A supplementation study in this population will be able to determine whether the genes identified on a cross-sectional basis do determine uptake of the nutritional supplement. We may also be able to identify specific demographic or lifestyle factors of non-responders which may help to explain the phenomenon.

  1. Carpentier S, Knaus M, Suh M. Associations between Lutein, Zeaxanthin, and Age-Related Macular Degeneration: An Overview. Clinical Reviews in Food Science and Nutrition. 2009 49:313-326
  2. Whitehead AJ, Mares J, Danis RP. Macular Pigment: A Review of Current Knowledge. Arch Opthamol. July 2006; 124: 1038-1045
  3. Ciulla TA, Curran-Celantano J, Cooper DA, et al. Macular pigment optical density in a midwestern sample. Ophthalmology. Apr 2001;108(4):730-737.
  4. Hammond BR, Jr., Caruso-Avery M. Macular pigment optical density in a Southwestern sample. Invest Ophthalmol Vis Sci. May 2000;41(6):1492-1497.
  5. Hammond BR, Jr., Curran-Celentano J, Judd S, et al. Sex differences in macular pigment optical density: relation to plasma carotenoid concentrations and dietary patterns. Vision Res. Jul 1996;36(13):2001-2012.
  6. Hammond BR, Jr., Wooten BR, Snodderly DM. Cigarette smoking and retinal carotenoids: implications for age-related macular degeneration. Vision Res. Sep 1996;36(18):3003-3009.
  7. Ciulla TA, Hammond BR, Jr. Macular pigment density and aging, assessed in the normal elderly and those with cataracts and age-related macular degeneration. Am J Ophthalmol. Oct 2004;138(4):582-587.
  8. Curran-Celentano J, Hammond BR, Jr., Ciulla TA, Cooper DA, Pratt LM, Danis RB. Relation between dietary intake, serum concentrations, and retinal concentrations of lutein and zeaxanthin in adults in a Midwest population. Am J Clin Nutr. Dec 2001;74(6):796-802.
  9. Nolan J, O'Donovan O, Kavanagh H, et al. Macular pigment and percentage of body fat. Invest Ophthalmol Vis Sci. Nov 2004;45(11):3940-3950.
  10. Carpentier S, Knaus M, Suh M. Associations between Lutein, Zeaxanthin, and Age-Related Macular Degeneration: An Overview. Critical Reviews in Food Science and Nutrition. 2009; 49(4): 313-326
  11. Bachmanov A, Beauchamp G. Taste Receptor Genes. Annual Review of Nutrition. 2007.27:389-414
  12. Hammond BR, Jr., Johnson EJ, Russell RM, et al. Dietary modification of human macular pigment density. Invest Ophthalmol Vis Sci. Aug 1997;38(9):1795-1801.
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Basic Science
Healthy
  • Dietary Supplement: Nutrof Total
    Antioxidant and trace element supplement
  • Dietary Supplement: Placebo
  • Experimental: Vitamin Supplement
    1 capsule of Nutrof Total made by Laboratories Thea for 16 weeks
    Intervention: Dietary Supplement: Nutrof Total
  • Placebo Comparator: Inert oil capsule
    1 capsule daily for 16 weeks
    Intervention: Dietary Supplement: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
May 2013
May 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • healthy volunteers,
  • male or female,
  • aged 18-50 years

Exclusion Criteria:

  • evidence of eye disease,
  • inability to give informed written consent,
  • any other health problem which would interfere with ability to adhere to the study protocol.
Both
18 Years to 50 Years
Yes
Not Provided
United Kingdom
 
NCT01778231
11/05v1
No
Ruth Hogg, Queen's University, Belfast
Queen's University, Belfast
Not Provided
Not Provided
Queen's University, Belfast
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP